BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems triggered by the production of autoantibodies. Previous clinical studies in humans and murine models suggest that type I interferons (IFNs) are important for the initiation and potentiation of SLE activity. METHODS: 65 consecutive patients with SLE were identified from the University of California, San Francisco Lupus Clinic with moderate-severe disease activity. 94 serological samples were collected. Type I IFN levels and the ability of plasma to induce expression of several surface markers of dendritic cell maturation were measured. RESULTS: Type I IFN levels correlated with the presence of cutaneous manifestations, and there was a trend towards correlation with renal disease. No correlation was found between type I IFN levels and neurological disease. Type I IFN levels correlated positively with the SLEDAI score and anti-dsDNA levels and inversely with C3 levels. Interestingly, type I IFN levels were highest in African American patients. SLE plasma also induced the expression of MHC class I, CD38, and CD123 on monocytes, and was blocked by the addition of a monoclonal antibody to IFNAR1. CONCLUSIONS: The pathogenic role of type I IFN is suggested by the induction of cell surface markers for dendritic cell maturation. The potential therapeutic utility of antibodies directed to either type I IFN or IFNAR1/IFNAR2 may be of interest in further studies.
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems triggered by the production of autoantibodies. Previous clinical studies in humans and murine models suggest that type I interferons (IFNs) are important for the initiation and potentiation of SLE activity. METHODS: 65 consecutive patients with SLE were identified from the University of California, San Francisco Lupus Clinic with moderate-severe disease activity. 94 serological samples were collected. Type I IFN levels and the ability of plasma to induce expression of several surface markers of dendritic cell maturation were measured. RESULTS: Type I IFN levels correlated with the presence of cutaneous manifestations, and there was a trend towards correlation with renal disease. No correlation was found between type I IFN levels and neurological disease. Type I IFN levels correlated positively with the SLEDAI score and anti-dsDNA levels and inversely with C3 levels. Interestingly, type I IFN levels were highest in African American patients. SLE plasma also induced the expression of MHC class I, CD38, and CD123 on monocytes, and was blocked by the addition of a monoclonal antibody to IFNAR1. CONCLUSIONS: The pathogenic role of type I IFN is suggested by the induction of cell surface markers for dendritic cell maturation. The potential therapeutic utility of antibodies directed to either type I IFN or IFNAR1/IFNAR2 may be of interest in further studies.
Authors: Monika Slavikova; Hana Schmeisser; Eva Kontsekova; Frantisek Mateicka; Ladislav Borecky; Peter Kontsek Journal: J Interferon Cytokine Res Date: 2003-03 Impact factor: 2.607
Authors: Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens Journal: Proc Natl Acad Sci U S A Date: 2003-02-25 Impact factor: 11.205
Authors: Sarah L Pogue; Benjamin T Preston; Joseph Stalder; Christopher R Bebbington; Pina M Cardarelli Journal: J Interferon Cytokine Res Date: 2004-02 Impact factor: 2.607
Authors: Arna Katewa; Yugang Wang; Jason A Hackney; Tao Huang; Eric Suto; Nandhini Ramamoorthi; Cary D Austin; Meire Bremer; Jacob Zhi Chen; James J Crawford; Kevin S Currie; Peter Blomgren; Jason DeVoss; Julie A DiPaolo; Jonathan Hau; Adam Johnson; Justin Lesch; Laura E DeForge; Zhonghua Lin; Marya Liimatta; Joseph W Lubach; Sami McVay; Zora Modrusan; Allen Nguyen; Chungkee Poon; Jianyong Wang; Lichuan Liu; Wyne P Lee; Harvey Wong; Wendy B Young; Michael J Townsend; Karin Reif Journal: JCI Insight Date: 2017-04-06
Authors: Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed Journal: Mol Med Date: 2007 Jan-Feb Impact factor: 6.354
Authors: Juan P Mackern-Oberti; Carolina Llanos; Claudia A Riedel; Susan M Bueno; Alexis M Kalergis Journal: Immunology Date: 2015-10-12 Impact factor: 7.397
Authors: William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader Journal: Atherosclerosis Date: 2014-01-10 Impact factor: 5.162
Authors: Iain J Abbott; Christina C Chang; Matthew J Skinner; Alison Street; Greg Perry; Catriona McLean; Edwina J Wright; Paul U Cameron Journal: J Med Case Rep Date: 2009-06-10